AzTrials
AzTrials

Intra-cytoplasmic Sperm Injection OutcomePhase 1NCT01563822

Does Flushing the Uterine Cavity With Follicular Fluid After Ovum Pick-up Improve Implantation Rates in ICSI Cycles?

A Phase 1 study testing Follicular fluid in people with Intra-cytoplasmic Sperm Injection Outcome, run by Nawara Mohamed Hashish at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background: Traditionally during ovum pick-up in ICSI, we aspirate the follicles for oocyte retrieval but unfortunately we don't make use of the follicular fluid (FF) and we discard it in spite of the fact that this does not happen in nature. The fallopian tube picks-up the FF with the oocyte during ovulation. Read more about this study

Who is it for?
Ages 20 to 38 years, women only
What is being tested?
Follicular fluid
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 siteEgypt
Study dates
Dec 2011to Jun 2012
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 38 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Maternal age ranges from 20-38 years.
  • Basal FSH < 10 mIU/ml.
  • BMI < 35 kg/m2.
  • Estradiol level > 1000 at the day of HCG administration.
  • Estradiol level < 4000 at the day of HCG administration.

Who cannot join

  • Presence of Endometriosis.
  • Presence of Hydrosalpinx.
  • Presence of vaginal infection.
  • Presence of galactorrhea.
  • Presence of hormonal disorders.
  • Severe male factor infertility:
  • Sperm Count < one million. Marked malformation
  • history of recurrent abortion.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Kasr El-Aini hospital

    Cairo

Other trials in Egypt

About this study

Official title: Phase I Study of the Effect of Flushing the Uterine Cavity With Follicular Fluid After Ovum Pick-up on Implantation Rates in ICSI Cycles

Background:

Traditionally during ovum pick-up in ICSI, we aspirate the follicles for oocyte retrieval but unfortunately we don't make use of the follicular fluid (FF) and we discard it in spite of the fact that this does not happen in nature. The fallopian tube picks-up the FF with the oocyte during ovulation. As this fluid contains stem cell factor and C-Kit receptor responsible for implantation and IGF responsible for endometrial growth and TGF that improves implantation. That's why flushing the endometrial cavity with FF after ovum pick-up might improve endometrial receptivity and implantation rates; the limiting step in ICSI.

Read more

Patients and Methods:

100 patients attending kasr El-Aini IVF center preparing for ICSI cycles are randomized into two groups. In the study group, flushing the endometrial cavity with 2ml of clear follicular fluid surrounding mature oocytes through an IUI catheter is done after ovum pick-up While in the control group, no flushing of the endometrial cavity with FF is done. The implantation rates and pregnancy rates in both groups will be assessed.

Read the detailed description

Introduction:

Looking at the process of IVF, we found that we only make use of the ovum and sperm and we neglect completely the valuable effect of the follicular fluid which is currently attracting a lot of attention. Several studies revealed a pivotal role played by this fluid in the process of fertilization and implantation as it is rich in growth factors as stem cell factor, transforming growth factor and insulin growth factor and cytokines (1,2).

Macciò study confirmed that follicular fluid (FF) contains factors that induce immunosuppression and explained that the immunosuppressive activity of FF is mediated by the specific inhibition of the production of IL-1 alpha and IL-2 and by the decreased expression of the CD25 (3).

During ovum pick-up, we aspirate all the FF and throw it away after ovum retrieval. This fluid normally enters the fallopian tubes while picking the ovum during ovulation in natural cycles and it reaches the uterine cavity as well and several studies suggested that it might have a crucial role in modifying uterine receptivity preparing the endometrium for the fertilized ovum arriving after 3 days as the TGF controls apoptosis, the IGF improves endometrial thickness and the immunosuppressive activity of the FF paves the way for the embryo to implant in the uterine cavity (4,5).

Actually Hunter study in 2007, provided circumstantial evidence for entry of follicular fluid into the Fallopian tubes, especially close to the time of ovulation, with the suggestion that such entry could modify the nature of endosalpingeal secretion and transudation. Thereafter, the spectrum of gonadal hormones in follicular fluid could be influencing uterine tissues in a local manner (5).

At the same time, it is a well known fact that implantation is the limiting step in IVF success , actually almost all IVF cycles succeed in offering fertilized ova giving rise to embryos at the different stages of development but unfortunately when we transfer them to the uterine cavity, 60% fail to implant.

Implantation is a complex initial step in the establishment of a successful pregnancy. Although embryo quality is an important determinant of implantation, temporally co-ordinated differentiation of endometrial cells to attain uterine receptivity and a synchronized dialogue between maternal and embryonic tissues are crucial. Optimizing endometrial receptivity in fertility treatment will improve success rate.

Several growth factors and cytokines appear to be involved in the process of implantation. Stem cell factor and its receptor c-kit regulate the progression and survival of germ cells and play an important role in follicular development. It is present in the follicular fluid however little information was available on the role of stem cell factor and its receptor in the process of blastocyst implantation. It was not until Mitsunari examined the expression of stem cell factor and its receptor in mouse embryos and in the stromal and epithelial cells of the uterine endometrium by reverse transcription -polymerase chain reaction . He illustrated that stem cell factor derived from endometrial cells and the implanting embryo exerts paracrine and autocrine action on the process of implantation by stimulating trophoblast outgrowth through its receptor c-kit (6).

Neglecting the importance of the follicular fluid and throwing it away during the process of IVF is actually a deviation from what happens in nature where the fallopian tube is intelligent enough to appreciate the value of this fluid and pick it up with the ovum.

That is why in this study, we want to mimic natural cycles and explore the benefits of flushing the uterine cavity with follicular fluid after ovum pick-up in improving implantation rates in ICSI cycles.

Materials and methods:

100 patients attending kasr El-Ainey IVF center preparing for ICSI cycles will be randomized into two groups.

In this prospective interventional study, the patients of both groups will receive the same induction protocol for controlled ovarian hyperstimulation which is the long protocol, our standard protocol in the center. Initial suppression of ovarian function with gonadotrophin releasing hormone agonist will start on day 21 of the preceeding cycle. Human menopausal gonadotrophin induction will start after confirmed ovarian down regulation by both laboratory investigations and ultrasound by daily intramuscular injection of 150-300 IU (Merional, IBSA) until at least 3 follicles reach 18 mm and serum estradiol level lies between 1000-4000 then 10000 IU, HCG is given.

Ovum pick-up is scheduled 35 hours later, where each follicle is aspirated in a separate tube and will be examined by the embryologist separately where:

  • The follicular fluid from empty follicles will be discarded, only the FF from follicles where mature oocytes were retrieved will be used.
  • The follicular fluid contaminated with blood will be discarded and would not be used, only the clear FF will be used.
  • No flushing was used after oocyte aspiration in order not to interfere with the concentration of growth factors in the FF .

After explaining the procedure and taking informed consent from the patients:

2ml of clear follicular fluid will be injected in the uterine cavity to flush the endometrium through an IUI catheter after performing mock transfer in the study group.

While, in the control group, no flushing of the endometrial cavity with FF is done.

In both groups, embryo transfer will be carried out 2-3 days later according to the condition of the embryos and pregnancy test will be carried out 14 days later.

The protocol was approved by the review board at kasr el-Aini hospital; IVF center at Cairo university.

Being tested
Follicular fluid
Keywords
Follicular Fluid, uterine cavity, Implantation rates, ICSI

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Follicular fluidBiological

    The intervention is flushing the uterine cavity with 2 ml of clear follicular fluid surrounding mature oocytes after ovum pick-up through an IUI catheter

Study groups in NCT01563822
Study groupRoleWhat they receive
follicular fluid groupExperimentalFollicular fluid group is the group in which flushing of the uterine cavity with follicular fluid after ovum pick-up is done.
Receives: Biological: Follicular fluid
control groupNo interventionControl group is the group in which flushing of the uterine cavity with follicular fluid after ovum pick-up is not done.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. pregnancy rate

    The main outcome is the pregnancy rate in ICSI cycles after flushing the uterine cavity with follicular fluid after ovum pick-up in the study group and comparing it with the control group.

    Measured: 17 days

Secondary outcomes (1)
  1. Implantation rate

    The secondary outcome is the implantation rate in ICSI cycles after flushing the uterine cavity with follicular fluid after ovum pick-up in the study group and comparing it with the control group.

    Measured: 17 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Mar 2012 (estimated)
  2. Study startDec 2011
  3. Primary completionJun 2012
  4. Study completionJun 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
100 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01563822
Sponsor's protocol ID
132012
Status last verified
Oct 2012
First submitted
20 Mar 2012
Last updated
10 Oct 2012
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Follicular fluid in people with Intra-cytoplasmic Sperm Injection Outcome, run by Nawara Mohamed Hashish at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Oct 2012. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

pregnancy rate (time frame: 17 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Oct 2012.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in